Skip to main content
Have a personal or library account? Click to login
Recent Advances on the Prevention and Management of Rheumatic Heart Disease Cover

Recent Advances on the Prevention and Management of Rheumatic Heart Disease

Open Access
|Feb 2025

References

  1. Ou Z, Yu D, Liang Y, et al. Global burden of rheumatic heart disease: Trends from 1990 to 2019. Arthritis Res Ther. 2022; 24(1):138. DOI: 10.1186/s13075-022-02829-3
  2. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: Update from the GBD 2019 Study. J Am Coll Cardiol. 2020; 76(25):29823021. DOI: 10.1016/j.jacc.2020.11.010
  3. Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990–2015. N Engl J Med. 2017; 377(8):713722. DOI: 10.1056/NEJMoa1603693
  4. Hibino M, Halkos ME, Murphy DA, et al. Age period cohort analysis of rheumatic heart disease in high-income countries. Clin Res Cardiol. 2023; 112(11):15681576. DOI: 10.1007/s00392-023-02168-6
  5. Safiri S, Mousavi SE, Noori M, et al. The burden of rheumatic heart disease in the Middle East and North Africa region, 1990–2019. Arch Cardiovasc Dis. 2023; 116(12):542554. DOI: 10.1016/j.acvd.2023.09.005
  6. Guan C, Xu W, Wu S, Zhang J. Rheumatic heart disease burden, trends, and inequalities in Asia, 1990–2019. Glob Health Action. 2023; 16(1):2215011. DOI: 10.1080/16549716.2023.2215011
  7. Coffey PM, Ralph AP, Krause VL. The role of social determinants of health in the risk and prevention of group A streptococcal infection, acute rheumatic fever and rheumatic heart disease: A systematic review. PLoS Negl Trop Dis. 2018; 12(6):e0006577. DOI: 10.1371/journal.pntd.0006577
  8. Steer AC. Historical aspects of rheumatic fever. J Paediatr Child Health. 2015; 51(1):2127. DOI: 10.1111/jpc.12808
  9. Bach JF, Chalons S, Forier E, et al. 10-year educational programme aimed at rheumatic fever in two French Caribbean islands. Lancet. 1996; 347(9002):644648. DOI: 10.1016/S0140-6736(96)91202-7
  10. Nordet P, Lopez R, Duenas A, Sarmiento L. Prevention and control of rheumatic fever and rheumatic heart disease: the Cuban experience (1986–1996–2002). Cardiovasc J Afr. 2008; 19(3):135140. https://www.ncbi.nlm.nih.gov/pubmed/18568172. Published 2008/06/24
  11. Bowen AC, Harris T, Holt DC, et al. Whole genome sequencing reveals extensive community-level transmission of group A Streptococcus in remote communities. Epidemiol Infect. 2016; 144(9):19911998. DOI: 10.1017/S095026881500326X
  12. Cordery R, Purba AK, Begum L, et al. Frequency of transmission, asymptomatic shedding, and airborne spread of Streptococcus pyogenes in schoolchildren exposed to scarlet fever: A prospective, longitudinal, multicohort, molecular epidemiological, contact-tracing study in England, UK. Lancet Microbe. 2022; 3(5):e366e375. DOI: 10.1016/S2666-5247(21)00332-3
  13. Bennett J, Zhang J, Leung W, et al. Rising ethnic inequalities in acute rheumatic fever and rheumatic heart disease, New Zealand, 2000–2018. Emerg Infect Dis. 2021; 27(1):3646. DOI: 10.3201/eid2701.191791
  14. Whitcombe AL, McGregor R, Bennett J, et al. Increased breadth of group a streptococcus antibody responses in children with acute rheumatic fever compared to precursor pharyngitis and skin infections. J Infect Dis. 2022; 226(1):167176. DOI: 10.1093/infdis/jiac043
  15. Rwebembera J, Cannon JW, Sanyahumbi A, et al. Research opportunities for the primary prevention and management of acute rheumatic fever and rheumatic heart disease: A National Heart, Lung, and Blood Institute workshop report. BMJ Glob Health. 2023; 8(Suppl 9). DOI: 10.1136/bmjgh-2023-012356
  16. Robertson KA, Volmink JA, Mayosi BM. Antibiotics for the primary prevention of acute rheumatic fever: a meta-analysis. BMC Cardiovasc Disord. 2005; 5(1):11. DOI: 10.1186/1471-2261-5-11
  17. Nalubwama H, Ndagire E, Sarnacki R, et al. Community perspectives on primary prevention of rheumatic heart disease in Uganda. Glob Heart. 2022; 17(1):5. DOI: 10.5334/gh.1094
  18. Parks T, Smeesters PR, Steer AC. Streptococcal skin infection and rheumatic heart disease. Curr Opin Infect Dis. 2012; 25(2):145153. DOI: 10.1097/QCO.0b013e3283511d27
  19. Thornley S, Marshall R, Jarrett P, Sundborn G, Reynolds E, Schofield G. Scabies is strongly associated with acute rheumatic fever in a cohort study of Auckland children. J Paediatr Child Health. 2018; 54(6):625632. DOI: 10.1111/jpc.13851
  20. Coates MM, Sliwa K, Watkins DA, et al. An investment case for the prevention and management of rheumatic heart disease in the African Union 2021–30: A modelling study. Lancet Glob Health. 2021; 9(7):e957e966. DOI: 10.1016/S2214-109X(21)00199-6
  21. Cannon JW, Wyber R. Modalities of group A streptococcal prevention and treatment and their economic justification. NPJ Vaccines. 2023; 8(1):59. DOI: 10.1038/s41541-023-00649-3
  22. Cohen JF, Bertille N, Cohen R, Chalumeau M. Rapid antigen detection test for group A streptococcus in children with pharyngitis. Cochrane Database Syst Rev. 2016; 7(7):CD010502. DOI: 10.1002/14651858.CD010502.pub2
  23. Tortorice D, Ferranna M, Bloom DE. Optimal global spending for group A Streptococcus vaccine research and development. NPJ Vaccines. 2023; 8(1):62. DOI: 10.1038/s41541-023-00646-6
  24. Azuar A, Jin W, Mukaida S, Hussein WM, Toth I, Skwarczynski M. Recent advances in the development of peptide vaccines and their delivery systems against group A Streptococcus. Vaccines (Basel). 2019; 7(3). DOI: 10.3390/vaccines7030058
  25. Walker MJ, Barnett TC, McArthur JD, et al. Disease manifestations and pathogenic mechanisms of group A Streptococcus. Clin Microbiol Rev. 2014; 27(2):264301. DOI: 10.1128/CMR.00101-13
  26. Massell BF, Honikman LH, Amezcua J. Rheumatic fever following streptococcal vaccination. Report of three cases. JAMA. 1969; 207(6):11151119. https://www.ncbi.nlm.nih.gov/pubmed/5818242. Published 1969/02/10
  27. Dale JB, Chiang EY, Lederer JW. Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol. 1993; 151(4):21882194. https://www.ncbi.nlm.nih.gov/pubmed/8345202. Published 1993/08/15
  28. Castro SA, Dorfmueller HC. A brief review on group A Streptococcus pathogenesis and vaccine development. R Soc Open Sci. 2021; 8(3):201991. DOI: 10.1098/rsos.201991
  29. Shea PR, Ewbank AL, Gonzalez-Lugo JH, et al. Group A Streptococcus emm gene types in pharyngeal isolates, Ontario, Canada, 2002–2010. Emerg Infect Dis. 2011; 17(11):20102017. DOI: 10.3201/eid1711.110159
  30. Davies MR, McIntyre L, Mutreja A, et al. Atlas of group A streptococcal vaccine candidates compiled using large-scale comparative genomics. Nat Genet. 2019; 51(6):10351043. DOI: 10.1038/s41588-019-0417-8
  31. Smeesters PR, McMillan DJ, Sriprakash KS, Georgousakis MM. Differences among group A streptococcus epidemiological landscapes: Consequences for M protein-based vaccines? Expert Rev Vaccines. 2009; 8(12):17051720. DOI: 10.1586/erv.09.133
  32. Dale JB, Walker MJ. Update on group A streptococcal vaccine development. Curr Opin Infect Dis. 2020; 33(3):244250. DOI: 10.1097/QCO.0000000000000644
  33. Pastural E, McNeil SA, MacKinnon-Cameron D, et al. Safety and immunogenicity of a 30-valent M protein-based group a streptococcal vaccine in healthy adult volunteers: A randomized, controlled phase I study. Vaccine. 2020; 38(6):13841392. DOI: 10.1016/j.vaccine.2019.12.005
  34. Sekuloski S, Batzloff MR, Griffin P, et al. Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial. PLoS One. 2018; 13(7):e0198658. DOI: 10.1371/journal.pone.0198658
  35. Dale JB, Aranha MP, Penfound TA, Salehi S, Smith JC. Structure-guided design of a broadly cross-reactive multivalent group a streptococcal vaccine. Vaccine. 2023; 41(40):58415847. DOI: 10.1016/j.vaccine.2023.08.026
  36. Alharbi N, Shalash AO, Koirala P, et al. Cholesterol as an inbuilt immunoadjuvant for a lipopeptide vaccine against group A Streptococcus infection. J Colloid Interface Sci. 2024; 663:4352. DOI: 10.1016/j.jcis.2024.02.134
  37. Pitirollo O, Di Benedetto R, Henriques P, et al. Elucidating the role of N-acetylglucosamine in group A Carbohydrate for the development of an effective glycoconjugate vaccine against group A Streptococcus. Carbohydr Polym. 2023; 311:120736. DOI: 10.1016/j.carbpol.2023.120736
  38. Gao NJ, Rodas Lima E, Nizet V. Immunobiology of the classical lancefield group A Streptococcal Carbohydrate Antigen. Infect Immun. 2021; 89(12):e0029221. DOI: 10.1128/IAI.00292-21
  39. Troese MJ, Burlet E, Cunningham MW, et al. Group A Streptococcus vaccine targeting the erythrogenic toxins SpeA and SpeB is safe and immunogenic in rabbits and does not induce antibodies associated with autoimmunity. Vaccines (Basel). 2023; 11(9). DOI: 10.3390/vaccines11091504
  40. Chen S, Ozberk V, Sam G, et al. Polymeric epitope-based vaccine induces protective immunity against group A Streptococcus. NPJ Vaccines. 2023; 8(1):102. DOI: 10.1038/s41541-023-00695-x
  41. Fan J, Toth I, Stephenson RJ. Recent scientific advancements towards a vaccine against group A Streptococcus. Vaccines (Basel). 2024; 12(3). DOI: 10.3390/vaccines12030272
  42. Osowicki J, Vekemans J, Kaslow DC, Friede MH, Kim JH, Steer AC. WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12–13 December 2016. Vaccine. 2018; 36(24):33973405. DOI: 10.1016/j.vaccine.2018.02.068
  43. Dougherty S, Okello E, Mwangi J, Kumar RK. Rheumatic heart disease: JACC focus seminar 2/4. J Am Coll Cardiol. 2023; 81(1):8194. DOI: 10.1016/j.jacc.2022.09.050
  44. Rwebembera J, Marangou J, Mwita JC, et al. 2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease. Nat Rev Cardiol. 2024; 21(4):250263. DOI: 10.1038/s41569-023-00940-9
  45. Francis JR, Whalley GA, Kaethner A, et al. Single-view echocardiography by nonexpert practitioners to detect rheumatic heart disease: A prospective study of diagnostic accuracy. Circ Cardiovasc Imaging. 2021; 14(8):e011790. DOI: 10.1161/CIRCIMAGING.120.011790
  46. Francis JR, Fairhurst H, Yan J, et al. Abbreviated echocardiographic screening for rheumatic heart disease by nonexperts with and without offsite expert review: A diagnostic accuracy study. J Am Soc Echocardiogr. 2023; 36(7):733745. DOI: 10.1016/j.echo.2023.02.007
  47. Elazrag A, Altahir A, Abbas A, et al. Handheld echocardiographic screening for rheumatic heart disease by non-experts in rural South Kordofan, Sudan: Supporting task shifting for control of a serious disease. Int J Cardiol. 2023; 377:99103. DOI: 10.1016/j.ijcard.2023.01.024
  48. Peck D, Rwebembera J, Nakagaayi D, et al. The use of artificial intelligence guidance for rheumatic heart disease screening by novices. J Am Soc Echocardiogr. 2023; 36(7):724732. DOI: 10.1016/j.echo.2023.03.001
  49. Edwards LA, Feng F, Iqbal M, et al. Machine learning for pediatric echocardiographic mitral regurgitation detection. J Am Soc Echocardiogr. 2023; 36(1):96104 e104. DOI: 10.1016/j.echo.2022.09.017
  50. Martins J, Nascimento ER, Nascimento BR, et al. Towards automatic diagnosis of rheumatic heart disease on echocardiographic exams through video-based deep learning. J Am Med Inform Assoc. 2021; 28(9):18341842. DOI: 10.1093/jamia/ocab061
  51. Gurney J, Chong A, Culliford-Semmens N, Tilton E, Wilson NJ, Sarfati D. The benefits and harms of rheumatic heart disease screening from the perspective of the screened population. Int J Cardiol. 2016; 221:734740. DOI: 10.1016/j.ijcard.2016.07.025
  52. Beaton A, Okello E, Rwebembera J, et al. Secondary Antibiotic Prophylaxis for Latent Rheumatic Heart Disease. N Engl J Med. 2022; 386(3):230240. DOI: 10.1056/NEJMoa2102074
  53. de Dassel JL, de Klerk N, Carapetis JR, Ralph AP. How many doses make a difference? An analysis of secondary prevention of rheumatic fever and rheumatic heart disease. J Am Heart Assoc. 2018; 7(24):e010223. DOI: 10.1161/JAHA.118.010223
  54. Ralph AP, Noonan S, Wade V, Currie BJ. The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. Med J Aust. 2021; 214(5):220227. DOI: 10.5694/mja2.50851
  55. Regmi PR, Dhungel M, Kafle R. Secondary prevention of rheumatic heart disease in nepal: Are we going backward? JNMA J Nepal Med Assoc. 2022; 60(253):832835. DOI: 10.31729/jnma.7861
  56. Ambari AM, Radi B, Dwiputra B, et al. Adherence to penicillin treatment is essential for effective secondary prevention of rheumatic heart disease: a systematic review and meta-analysis. Ann Med Surg (Lond). 2024; 86(4):21162123. DOI: 10.1097/MS9.0000000000001833
  57. Longenecker CT, Morris SR, Aliku TO, et al. Rheumatic heart disease treatment cascade in Uganda. Circ Cardiovasc Qual Outcomes. 2017; 10(11). DOI: 10.1161/CIRCOUTCOMES.117.004037
  58. Fall N, Odong F, Thembo J, et al. User-centered design to develop automated short message service messaging for patient support of rheumatic heart disease secondary antibiotic prophylaxis. J Am Heart Assoc. 2024; 13(2):e031252. DOI: 10.1161/JAHA.123.031252
  59. Dixit J, Prinja S, Jyani G, et al. Evaluating efficiency and equity of prevention and control strategies for rheumatic fever and rheumatic heart disease in India: an extended cost-effectiveness analysis. Lancet Glob Health. 2023; 11(3):e445e455. DOI: 10.1016/S2214-109X(22)00552-6
  60. Rwebembera J, Ndagire E, Carvalho N, et al. Intramuscular versus Enteral Penicillin Prophylaxis to Prevent Progression of Rheumatic Heart Disease: Study protocol for a non-inferiority randomized trial (the GOALIE trial). Am Heart J. 2024. DOI: 10.1016/j.ahj.2024.05.012
  61. Karthikeyan G, Kothari SS. How should the burden of rheumatic heart disease be reduced? Lancet Glob Health. 2023; 11(3):e316e317. DOI: 10.1016/S2214-109X(23)00011-6
  62. Francia CJ, Fraser JF, Justo R, Cassimatis J, Manoy S, Johnston LM. Follow-up echocardiographic changes in children and youth aged >25 years with latent rheumatic heart disease: A systematic review and meta-analysis of global data. Int J Cardiol. 2024; 403:131911. DOI: 10.1016/j.ijcard.2024.131911
  63. Kim JY, Kim SH, Myong JP, et al. Outcomes of Direct Oral Anticoagulants in Patients With Mitral Stenosis. J Am Coll Cardiol. 2019; 73(10):11231131. DOI: 10.1016/j.jacc.2018.12.047
  64. Connolly SJ, Karthikeyan G, Ntsekhe M, et al. Rivaroxaban in Rheumatic Heart Disease-Associated Atrial Fibrillation. N Engl J Med. 2022; 387(11):978988. DOI: 10.1056/NEJMoa2209051
  65. Mutagaywa RK, Kifai E, Elinisa M, et al. Comparison between interventional versus medical therapy in patients with rheumatic mitral valve stenosis in Tanzania. Eur J Clin Invest. 2024; 54(3):e14114. DOI: 10.1111/eci.14114
  66. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021; 143(5):e72e227. DOI: 10.1161/CIR.0000000000000923
  67. Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022; 43(7):561632. DOI: 10.1093/eurheartj/ehab395
  68. Desnos C, Iung B, Himbert D, et al. Temporal Trends on Percutaneous Mitral Commissurotomy: 30 Years of Experience. J Am Heart Assoc. 2019; 8(13):e012031. DOI: 10.1161/JAHA.119.012031
  69. Ko KY, Cho I, Kim DY, et al. Optimizing Percutaneous Mitral Valvuloplasty for Rheumatic Mitral Stenosis – Clinical Significance of Changes in Mitral Valve Area. Circ J. 2024. DOI: 10.1253/circj.CJ-23-0552
  70. Yasmin F, Jawed S, Najeeb H, et al. Comparative efficacy and safety of mitral valve repair versus mitral valve replacement in Rheumatic heart disease: A high-value care systematic review and meta-analysis. Curr Probl Cardiol. 2024; 49(6):102530. DOI: 10.1016/j.cpcardiol.2024.102530
  71. Lee HA, Chang FC, Yeh JK, et al. Mitral valve repair vs. replacement by different etiologies – A nationwide population-based cohort study. Circ J. 2024; 88(4):568578. DOI: 10.1253/circj.CJ-23-0640
  72. Sliwa K, Johnson MR, Zilla P, Roos-Hesselink JW. Management of valvular disease in pregnancy: A global perspective. Eur Heart J. 2015; 36(18):10781089. DOI: 10.1093/eurheartj/ehv050
  73. European Society of G, Association for European Paediatric C, German Society for Gender M, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32(24):31473197. DOI: 10.1093/eurheartj/ehr218
  74. Vitale N, De Feo M, De Santo LS, Pollice A, Tedesco N, Cotrufo M. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999; 33(6):16371641. DOI: 10.1016/S0735-1097(99)00044-3
  75. Pieper PG, Balci A, Van Dijk AP. Pregnancy in women with prosthetic heart valves. Neth Heart J. 2008; 16(12):406411. DOI: 10.1007/BF03086187
  76. Elkayam U, Goland S. The search for a safe and effective anticoagulation regimen in pregnant women with mechanical prosthetic heart valves. J Am Coll Cardiol. 2012; 59(12):11161118. DOI: 10.1016/j.jacc.2011.12.018
  77. McLintock C, McCowan LM, North RA. Maternal complications and pregnancy outcome in women with mechanical prosthetic heart valves treated with enoxaparin. BJOG. 2009; 116(12):15851592. DOI: 10.1111/j.1471-0528.2009.02299.x
  78. Chen CY, Chan YH, Wu VC, et al. Bioprosthetic versus mechanical mitral valve replacements in patients with rheumatic heart disease. J Thorac Cardiovasc Surg. 2023; 165(3):10501060 e1058. DOI: 10.1016/j.jtcvs.2021.03.033
  79. Zilla P, Human P, Pennel T. Mechanical valve replacement for patients with rheumatic heart disease: the reality of INR control in Africa and beyond. Front Cardiovasc Med. 2024; 11:1347838. DOI: 10.3389/fcvm.2024.1347838
DOI: https://doi.org/10.5334/gh.1402 | Journal eISSN: 2211-8179
Language: English
Submitted on: Aug 27, 2024
Accepted on: Feb 7, 2025
Published on: Feb 21, 2025
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2025 Jiawen Zhang, Songhao Jia, Yuhe Chen, Jie Han, Hongjia Zhang, Wenjian Jiang, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.